(Q37747381)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20455679%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

review article

1 reference

title

Levofloxacin in the treatment of community-acquired pneumonia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20455679%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20455679%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Ayman M Noreddin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20455679%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

1 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20455679%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anti-infective Therapy

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20455679%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20455679%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20455679%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

505-514

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20455679%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology of community-acquired pneumonia in adults: a population-based study

2 February 2020

cites work

1 reference

Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain.

21 January 2018

1 reference

Adult community-acquired pneumonia in Malaysia: prediction of mortality from severity assessment on admission

21 January 2018

1 reference

Hospitalization for pneumonia in the Cardiovascular Health Study: incidence, mortality, and influence on longer-term survival

21 January 2018

1 reference

The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens

21 January 2018

1 reference

Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy

21 January 2018

1 reference

Treatment costs of community-acquired pneumonia in an employed population

21 January 2018

1 reference

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia

21 January 2018

1 reference

Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation

21 January 2018

1 reference

Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database.

21 January 2018

1 reference

Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia

21 January 2018

1 reference

Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan.

21 January 2018

1 reference

Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina

21 January 2018

1 reference

Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients

21 January 2018

1 reference

Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan

21 January 2018

1 reference

Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia

21 January 2018

1 reference

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

Guidelines for the management of adult lower respiratory tract infections

21 January 2018

1 reference

Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?

21 January 2018

1 reference

Phenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital

21 January 2018

1 reference

Comparative antimicrobial susceptibility of respiratory tract pathogens

21 January 2018

1 reference

Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management

21 January 2018

1 reference

Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.

21 January 2018

1 reference

Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study

21 January 2018

1 reference

Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.

21 January 2018

1 reference

Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study

21 January 2018

1 reference

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

21 January 2018

1 reference

21 January 2018

1 reference

A journey in the world of DNA rings and beyond

21 January 2018

1 reference

In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups

21 January 2018

1 reference

Levofloxacin: a review of its use in the treatment of bacterial infections in the United States

21 January 2018

1 reference

Moxifloxacin: a review of its use in the management of bacterial infections

21 January 2018

1 reference

Levofloxacin: an updated review of its use in the treatment of bacterial infections

21 January 2018

1 reference

Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States

21 January 2018

1 reference

Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).

21 January 2018

1 reference

Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY An

21 January 2018

1 reference

In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone

21 January 2018

1 reference

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents

21 January 2018

1 reference

Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.

21 January 2018

1 reference

Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients

21 January 2018

1 reference

Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States

21 January 2018

1 reference

Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

21 January 2018

1 reference

In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe

21 January 2018

1 reference

In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae

21 January 2018

1 reference

In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae

21 January 2018

1 reference

The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae

21 January 2018

1 reference

Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.

21 January 2018

1 reference

Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing

21 January 2018

1 reference

In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas

21 January 2018

1 reference

Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas

21 January 2018

1 reference

Bactericidal activity of levofloxacin against Mycoplasma pneumoniae

21 January 2018

1 reference

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm

21 January 2018

1 reference

Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas

21 January 2018

1 reference

Surveillance of resistance in bacteria causing community-acquired respiratory tract infections

21 January 2018

1 reference

Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.

21 January 2018

1 reference

Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa

21 January 2018

1 reference

Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin

21 January 2018

1 reference

Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001-2005).

21 January 2018

1 reference

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study

21 January 2018

1 reference

Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers

21 January 2018

1 reference

Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli

21 January 2018

1 reference

Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects

21 January 2018

1 reference

Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults

21 January 2018

1 reference

Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults

21 January 2018

1 reference

Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease

21 January 2018

1 reference

Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation

21 January 2018

1 reference

Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose

21 January 2018

1 reference

A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis

21 January 2018

1 reference

A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis

21 January 2018

1 reference

A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.

21 January 2018

1 reference

Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens

21 January 2018

1 reference

A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia

21 January 2018

1 reference

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia

21 January 2018

1 reference

Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.

21 January 2018

1 reference

Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections.

21 January 2018

1 reference

Antibiotic Prescription for Community-Acquired Pneumonia in the Intensive Care Unit: Impact of Adherence to Infectious Diseases Society of America Guidelines on Survival

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERI.10.35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20455679%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference